Biocon is currently trading at Rs. 378.35, up by 3.10 points or 0.83% from its previous closing of Rs. 375.25 on the BSE.
The scrip opened at Rs. 372.20 and has touched a high and low of Rs. 382.00 and Rs. 369.50 respectively. So far 347497 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 424.95 on 18-Nov-2025 and a 52 week low of Rs. 290.80 on 03-Mar-2025.
Last one week high and low of the scrip stood at Rs. 389.20 and Rs. 366.45 respectively. The current market cap of the company is Rs. 61318.94 crore.
The promoters holding in the company stood at 54.45%, while Institutions and Non-Institutions held 29.10% and 16.45% respectively.
Biocon has reported a net loss of Rs 76.40 crore for the third quarter ended December 31, 2025 as compared to net profit of Rs 584.00 crore for the same quarter in the previous year. However, the total income of the company increased by 11.02% at Rs 696.10 crore for Q3FY26 as compared to Rs 627.00 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported over five-fold jump in its net profit at Rs 143.80 crore for the third quarter ended December 31, 2025 as compared to Rs 25.10 crore for the same quarter in the previous year. The total income of the company increased by 11.26% at Rs 4,290.30 crore for Q3FY26 as compared to Rs 3,856.20 crore for the corresponding quarter previous year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: